fda category 2 bulk drug substances bpc-157 compounding list just got voted in favor to be added to the 503A list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank The experts will take votes

Aqueous solutions of poloxamers are stable in the presence of acids, alkalis, and metal ions

A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans

Figure 1 4 Drug delivery for Alzheimer's disease: formulations, ideal properties, systemically relevant effects, and delivery strategies of nanoparticles 4.1 Ideal physicochemical properties of nanoparticles for Alzheimer's disease 4.1.1 Size and charge Basically, for the treatment of AD and other central nervous system (CNS) disorders, nanoparticles with diameters of ~200 nm are considered optimal for the systemic pathway, as larger nanoparticles are more likely to be cleared by the reticuloendothelial system (RES) (Markova et al., 2022)

Contraindications and Precautions Do NOT use AOD-9604 if you: Are pregnant, trying to conceive, or breastfeeding (no safety data in pregnancy/lactation) Have active cancer or history of malignancy (peptide effects on existing cancer unknown) Are under 18 years of age (pediatric safety not established) Have known hypersensitivity to peptides or benzyl alcohol (in bacteriostatic water) Have severe kidney or liver disease without physician clearance Use with caution and enhanced monitoring if you have: Diabetes or glucose metabolism disorders (monitor blood sugar closely despite no expected impact) Cardiovascular disease (comprehensive cardiac evaluation recommended) Thyroid disorders (monitor thyroid function during therapy) History of migraines (may increase headache frequency in susceptible individuals) Drug Interactions Limited formal drug interaction studies exist for AOD-9604

Current treatments are largely palliative and do not address the underlying fibrosis